Bugworks Research, a Bangalore, India and Delaware, USA-based biopharma startup designing first-in-class antibiotics, completed a $9M Series A financing.
The round was led by University of Tokyo Edge Capital (UTEC) Japan, with syndication from Acquipharma Holdings, 3ONE4 Capital and other prominent biotech-focused global angels. In conjunction with the funding, Dr. Atsushi Usami, Partner at UTEC, will be joining Bugworks’ Board of Directors.
Led by Dr. Anand Anandkumar, CEO, Bugworks is advancing a novel bacterial topoisomerase inhibitor (NBTI) effective against a very broad spectrum of multi-drug resistant bacterial pathogens.
This first-in-class antibiotic was designed using ELUDE, the company’s proprietary efflux-pump avoidance platform, which enables the design of novel, differentiated antibiotics to cure hospital, community and bio-threat infections. Bugworks’ NBTI is a dual target small molecule inhibitor, with very low potential to create resistant strains, effective against all pathogens on the WHO Critical, High & Medium priority list as well as the CDC bio-threat bacterial pathogens.